Core Insights - Enlivex Therapeutics Ltd. has received a notice of allowance from the Japanese Patent Office for a patent application related to therapeutic apoptotic cells for the treatment of osteoarthritis, which will enhance its intellectual property protection until at least 2040 [1][2] - The company aims to develop Allocetra™ as a next-generation cell therapy for osteoarthritis, addressing a significant unmet medical need in a market with limited treatment options [2] Industry Overview - Osteoarthritis is the most prevalent form of arthritis, affecting over 32.5 million Americans and more than 300 million people globally, with projections indicating that 78 million Americans will have osteoarthritis by 2040 [3] - Symptomatic knee osteoarthritis is particularly common, with 40% of men and 47% of women likely to develop it in their lifetimes, leading to over one million hospitalizations annually in the U.S. primarily for total joint replacement [3] - Currently, there are no FDA or EMA approved medications that can effectively halt, slow, or reverse the structural damage associated with osteoarthritis [3] Company Profile - Enlivex is focused on macrophage reprogramming immunotherapy, specifically developing Allocetra™, a universal, off-the-shelf cell therapy aimed at restoring macrophages to their homeostatic state, which is essential for immune system balance [4]
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis